Jun Haginaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jun Haginaka has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Hisami Matsunaga
School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, 11-68, Koshien Kyuban-cho, Nishinomiya 663-8179, Japan
14 shared publicationsTetsutaro Kimachi
School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, 11-68, Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan
5 shared publicationsHiromi Tabo
School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya, Japan
4 shared publicationsYukari Nakamura
School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, 11-68, Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan
4 shared publicationsArisa Kubo
School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, 11-68, Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan
3 shared publications- Bezhan Chankvetadze
Institute of Physical and Analytical Chemistry, School of Exact and Natural Sciences, Tbilisi State University, Tbilisi, Georgia
3 shared publications
Latest Publications
- 13 October 2026
- Published by Wiley in Electrophoresis
Preparation of Monodispersed Molecularly Imprinted Polymers for Abiraterone and Its Derivatives and Evaluation of Their Retention and Molecular Recognition Properties
Monodispersed molecularly imprinted polymers (MIPs) for abiraterone (Abi), 5ʹ‐chloroabiraterone (5ʹ‐ClAbi), 5ʹ‐methylabiraterone (5ʹ‐MeAbi), and 6ʹ‐methylabiraterone (6ʹ‐MeAbi) (MIP Abi , MIP 5ʹ‐ClAbi , MIP 5ʹ‐MeAbi , and MIP 6ʹ‐MeAbi , respectively) were prepared using methacrylic acid (MAA) and ethylene glycol dimethacrylate (EDMA) as a functional monomer and a crosslinker, respectively, by multistep swelling and polymerization. The molar ratio of the template molecule to MAA and EDMA was 2:7:25. The retention and molecular recognition properties of the non‐imprinted polymer and MIPs (MIP Abi , MIP 5ʹ‐ClAbi , MIP 5ʹ‐MeAbi , and MIP 6ʹ‐MeAbi ) were evaluated using a mobile phase consisting of sodium phosphate buffer and acetonitrile in reversed‐phase liquid chromatography (LC). Abi, 5ʹ‐MeAbi, and 6ʹ‐MeAbi showed the highest retention on these MIPs in a mobile phase consisting of sodium phosphate buffer and acetonitrile (50:50) at pH 5.7, whereas 5ʹ‐ClAbi exhibited the highest retention in a mobile phase consisting of sodium phosphate buffer and acetonitrile (50:50) at pH 3.7. On the other hand, the imprinting factors of the template molecules followed the order MIP 5ʹ‐ClAbi < MIP 5ʹ‐MeAbi < MIP 6ʹ‐MeAbi < MIP Abi . The DFT calculations suggested two hydrogen‑bonding interactions between the (substituted) pyridines and the hydroxy groups of Abi and its derivatives with MAAs in the gas phase. The interaction energies followed the order MIP 5ʹ‐ClAbi < MIP Abi < MIP 5ʹ‐MeAbi < MIP 6ʹ‐MeAbi . These results suggested that ionic or hydrogen‐bonding interactions and hydrophobic interactions could work for the retention and molecular recognition of Abi and its derivatives on these MIPs in reversed‐phase mode.
- 13 October 2026
- Published by Wiley in Electrophoresis
Preparation of Monodispersed Molecularly Imprinted Polymers for Abiraterone and Its Derivatives and Evaluation of Their Retention and Molecular Recognition Properties
Monodispersed molecularly imprinted polymers (MIPs) for abiraterone (Abi), 5ʹ‐chloroabiraterone (5ʹ‐ClAbi), 5ʹ‐methylabiraterone (5ʹ‐MeAbi), and 6ʹ‐methylabiraterone (6ʹ‐MeAbi) (MIP Abi , MIP 5ʹ‐ClAbi , MIP 5ʹ‐MeAbi , and MIP 6ʹ‐MeAbi , respectively) were prepared using methacrylic acid (MAA) and ethylene glycol dimethacrylate (EDMA) as a functional monomer and a crosslinker, respectively, by multistep swelling and polymerization. The molar ratio of the template molecule to MAA and EDMA was 2:7:25. The retention and molecular recognition properties of the non‐imprinted polymer and MIPs (MIP Abi , MIP 5ʹ‐ClAbi , MIP 5ʹ‐MeAbi , and MIP 6ʹ‐MeAbi ) were evaluated using a mobile phase consisting of sodium phosphate buffer and acetonitrile in reversed‐phase liquid chromatography (LC). Abi, 5ʹ‐MeAbi, and 6ʹ‐MeAbi showed the highest retention on these MIPs in a mobile phase consisting of sodium phosphate buffer and acetonitrile (50:50) at pH 5.7, whereas 5ʹ‐ClAbi exhibited the highest retention in a mobile phase consisting of sodium phosphate buffer and acetonitrile (50:50) at pH 3.7. On the other hand, the imprinting factors of the template molecules followed the order MIP 5ʹ‐ClAbi < MIP 5ʹ‐MeAbi < MIP 6ʹ‐MeAbi < MIP Abi . The DFT calculations suggested two hydrogen‑bonding interactions between the (substituted) pyridines and the hydroxy groups of Abi and its derivatives with MAAs in the gas phase. The interaction energies followed the order MIP 5ʹ‐ClAbi < MIP Abi < MIP 5ʹ‐MeAbi < MIP 6ʹ‐MeAbi . These results suggested that ionic or hydrogen‐bonding interactions and hydrophobic interactions could work for the retention and molecular recognition of Abi and its derivatives on these MIPs in reversed‐phase mode.
- 12 September 2026
- Published by Elsevier in Journal of Chromatography A
- Vol. 1787
Investigation of the retention mechanism of abiraterone and its metabolites on ODS stationary phases using computational chemistry
- 12 September 2026
- Published by Elsevier in Journal of Chromatography A
- Vol. 1787
Investigation of the retention mechanism of abiraterone and its metabolites on ODS stationary phases using computational chemistry
- 23 November 2025
- Published by Springer Nature
- Vol. 2994, 339-348
Molecularly Imprinted Polymer-Based Chiral Stationary Phases for Chromatographic Enantioseparation
The synthesis of molecularly imprinted polymer (MIP)-based chiral stationary phases (CSPs) by precipitation polymerization or multistep swelling and polymerization and their application are described. Monodisperse, spherical MIP particles, whose diameters are about 5 μm, are prepared by those methods using a chiral template molecule. The obtained MIPs are suitable for enantioseparation of the target compound(s) in liquid chromatography (LC). Specifically, procedures for the synthesis of MIP-based chiral stationary phases by precipitation polymerization and multistep swelling and polymerization, respectively, for the enantioseparation of nicotine and warfarin, as well as the latter derivatives, are described.
- 23 November 2025
- Published by Springer Nature
- Vol. 2994, 339-348
Molecularly Imprinted Polymer-Based Chiral Stationary Phases for Chromatographic Enantioseparation
The synthesis of molecularly imprinted polymer (MIP)-based chiral stationary phases (CSPs) by precipitation polymerization or multistep swelling and polymerization and their application are described. Monodisperse, spherical MIP particles, whose diameters are about 5 μm, are prepared by those methods using a chiral template molecule. The obtained MIPs are suitable for enantioseparation of the target compound(s) in liquid chromatography (LC). Specifically, procedures for the synthesis of MIP-based chiral stationary phases by precipitation polymerization and multistep swelling and polymerization, respectively, for the enantioseparation of nicotine and warfarin, as well as the latter derivatives, are described.
- Open Access
- 18 November 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (24) , e202500675
Synthesis of the Abiraterone Derivatives 5α‐ and 5β‐Δ 1 ‐Abiraterone and Structural Determination of an Unknown Metabolite in Human Serum Derived from Oral Abiraterone Acetate
Abiraterone (Abi) acetate, an anticancer drug, produces metabolites in the serum of patients with prostate cancer. Three unknown metabolites of Abi are previously discovered and the structures of two of these compounds are determined by comparing their LC‐based retention times with those of synthesized compounds. However, the structure of the third metabolite is not identified. Herein, two new Abi derivatives, 5α‐Δ 1 ‐abiraterone (5α‐D1A) and 5β‐Δ 1 ‐abiraterone (5β‐D1A), with a molecular weight of 348, are successfully synthesized as candidates for the third unknown metabolite. 5β‐D1A is confirmed as this third metabolite based on its retention time in the extracted ion chromatogram. The metabolic pathway may have formed 5β‐D1A rather than 5α‐D1A because of the higher activity of steroid 5β‐reductase compared with that of 5α‐reductase. These findings are expected to lead to the discovery of new metabolic pathways.
- 18 November 2025
- Published by Wiley in ChemBioChem
- Vol. 26 (24) , e202500675
Open AccessSynthesis of the Abiraterone Derivatives 5α‐ and 5β‐Δ 1 ‐Abiraterone and Structural Determination of an Unknown Metabolite in Human Serum Derived from Oral Abiraterone Acetate
Abiraterone (Abi) acetate, an anticancer drug, produces metabolites in the serum of patients with prostate cancer. Three unknown metabolites of Abi are previously discovered and the structures of two of these compounds are determined by comparing their LC‐based retention times with those of synthesized compounds. However, the structure of the third metabolite is not identified. Herein, two new Abi derivatives, 5α‐Δ 1 ‐abiraterone (5α‐D1A) and 5β‐Δ 1 ‐abiraterone (5β‐D1A), with a molecular weight of 348, are successfully synthesized as candidates for the third unknown metabolite. 5β‐D1A is confirmed as this third metabolite based on its retention time in the extracted ion chromatogram. The metabolic pathway may have formed 5β‐D1A rather than 5α‐D1A because of the higher activity of steroid 5β‐reductase compared with that of 5α‐reductase. These findings are expected to lead to the discovery of new metabolic pathways.
- Open Access
- 17 January 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (4) , 445-454
A Phase II Trial of Abiraterone With Dutasteride for Second‐Generation Antiandrogen‐ and Chemotherapy‐Naïve Patients With Castration‐Resistant Prostate Cancer
The development of a novel therapy to overcome primary and acquired resistance to abiraterone is an unmet need. This study aimed to evaluate the efficacy and safety of adding 5 alpha-reductase inhibitor dutasteride to abiraterone, explore proof of concept, and identify candidates suitable for combination therapy. This phase II, single-arm, and open-label study enrolled second-generation antiandrogen- and chemotherapy-naive patients with castration-resistant prostate cancer. Patients received abiraterone and prednisolone for 4 weeks, followed by adding dutasteride. The primary end point was a 50% prostate-specific antigen response rate. Serum concentrations of abiraterone and its metabolites as well as HSD3B1 and SRD5A2 genotypes were measured. The association between drug metabolism and genotypes and their impact on the efficacy of combination therapy were assessed. Among 21 patients, 18 (85.7%) achieved >= 50% PSA reduction. Median time to treatment failure was not reached during the median follow-up of 15.4 months. No patients experienced grade >= 3 adverse events. Although dutasteride reduced serum 3-keto-5 alpha-abiraterone concentrations, higher serum 3-keto-5 alpha-abiraterone concentrations on combination therapy were associated with a shorter time to treatment failure. HSD3B1 and SRD5A2 genotypes were associated with serum Delta 4-abiraterone and 3-keto-5 alpha-abiraterone concentrations before adding dutasteride, respectively. Time to treatment failure was longer in patients with homozygous wild-type HSD3B1, but comparable between those with the SRD5A2 genotype. The promising outcomes of this study warrant further investigation of combination therapy in a randomized trial. Stratification by HSD3B1 and SRD5A2 genetic profiles might identify patients suitable for combination therapy.
- 17 January 2023
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 63 (4) , 445-454
Open AccessA Phase II Trial of Abiraterone With Dutasteride for Second‐Generation Antiandrogen‐ and Chemotherapy‐Naïve Patients With Castration‐Resistant Prostate Cancer
The development of a novel therapy to overcome primary and acquired resistance to abiraterone is an unmet need. This study aimed to evaluate the efficacy and safety of adding 5 alpha-reductase inhibitor dutasteride to abiraterone, explore proof of concept, and identify candidates suitable for combination therapy. This phase II, single-arm, and open-label study enrolled second-generation antiandrogen- and chemotherapy-naive patients with castration-resistant prostate cancer. Patients received abiraterone and prednisolone for 4 weeks, followed by adding dutasteride. The primary end point was a 50% prostate-specific antigen response rate. Serum concentrations of abiraterone and its metabolites as well as HSD3B1 and SRD5A2 genotypes were measured. The association between drug metabolism and genotypes and their impact on the efficacy of combination therapy were assessed. Among 21 patients, 18 (85.7%) achieved >= 50% PSA reduction. Median time to treatment failure was not reached during the median follow-up of 15.4 months. No patients experienced grade >= 3 adverse events. Although dutasteride reduced serum 3-keto-5 alpha-abiraterone concentrations, higher serum 3-keto-5 alpha-abiraterone concentrations on combination therapy were associated with a shorter time to treatment failure. HSD3B1 and SRD5A2 genotypes were associated with serum Delta 4-abiraterone and 3-keto-5 alpha-abiraterone concentrations before adding dutasteride, respectively. Time to treatment failure was longer in patients with homozygous wild-type HSD3B1, but comparable between those with the SRD5A2 genotype. The promising outcomes of this study warrant further investigation of combination therapy in a randomized trial. Stratification by HSD3B1 and SRD5A2 genetic profiles might identify patients suitable for combination therapy.
- 22 July 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 219, 114957
Selected papers from the 31st International Symposium on Pharmaceutical and Biomedical Analysis (PBA2021)
- 22 July 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 219, 114957
Selected papers from the 31st International Symposium on Pharmaceutical and Biomedical Analysis (PBA2021)
- Open Access
- 1 July 2022
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 70 (7) , 458-468
Progress in Chiral Stationary Phases Based on Proteins and Glycoproteins
A lot of chiral stationary phases (CSPs) have been introduced for the purpose of analytical and preparative separations of enantiomers. CSPs based on proteins and glycoproteins have unique properties among those CSPs. This review article deals with the preparation of CSPs based on proteins and glycoproteins, their chiral recognition properties and mechanisms, focusing on the CSPs investigated in our group. The dealt proteins and glycoproteins are including bovine serum albumin, human serum albumin, lysozyme, pepsin, human α1-acid glycoprotein (AGP), chicken ovomucoid and chicken ovoglycoprotein (named chicken AGP).
- 1 July 2022
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 70 (7) , 458-468
Open AccessProgress in Chiral Stationary Phases Based on Proteins and Glycoproteins
A lot of chiral stationary phases (CSPs) have been introduced for the purpose of analytical and preparative separations of enantiomers. CSPs based on proteins and glycoproteins have unique properties among those CSPs. This review article deals with the preparation of CSPs based on proteins and glycoproteins, their chiral recognition properties and mechanisms, focusing on the CSPs investigated in our group. The dealt proteins and glycoproteins are including bovine serum albumin, human serum albumin, lysozyme, pepsin, human α1-acid glycoprotein (AGP), chicken ovomucoid and chicken ovoglycoprotein (named chicken AGP).
- Open Access
- 3 January 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 210, 114567
In memory of Professor Sergio Pinzauti
- 3 January 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 210, 114567
Open AccessIn memory of Professor Sergio Pinzauti